Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
When researchers reference all four compounds together, its typically because each represents a different node in metabolic and growth-hormone research: AOD-9604 for its fragment-based lipid pathway, MOTS-c for mitochondrial signaling, Tesamorelin for GHRH receptor stimulation, and Ipamorelin for ghrelin receptor-mediated growth hormone release
No injectables necessary Water/Aqua/Eau, Propanediol, Pantethine, Glycerin, Tetrahexyldecyl Ascorbate, S-Palmitoylglutathione, Dimethyl MEA, Palmitoyl Tripeptide-38, Acetyl Tyrosine, Avena Sativa (Oat) Kernel Extract, Xanthan Gum, Macadamia Ternifolia Seed Oil, Linum Usitatissimum (Linseed) Seed Oil, Salvia Hispanica Seed Oil, Silica Cetyl Silylate, Ethylhexylglycerin, Sodium Hyaluronate, Helianthus Annuus (Sunflower) Seed Oil, Rosmarinus Officinalis (Rosemary) Leaf Extract, Tetrasodium Glutamate Diacetate, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Caprylyl Glycol, Hydroxypropyl Cyclodextrin, Phenoxyethanol, Silica, Titanium Dioxide (CI 77891), Iron Oxides (CI 77491)
10.2337/db12-1498 108 WiseR
Emerging evidence from single-cell multi-omics, spatial transcriptomics, metabolic imaging, and early-phase clinical trials targeting HIF signaling, angiogenic pathways, and metabolic enzymes has uncovered actionable vulnerabilities in hypoxia-driven malignancies
